BAJAJ BROKING

Notification close image
No new Notification messages
card image
Travel Food Services IPO is Open!
Apply for the Travel Food Services IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

16154

0

REMUS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

REMUS PHARMACEUTICALS L performance

Today’s low

Today’s high

₹ 940.00 ₹ 1021.80
₹ 954.25

52 week low

52 week high

₹ 890.53 ₹ 1417.38
₹ 954.25

Open Price

₹ 989.00

Prev. Close

₹ 1937.25

Volume (Shares)

6500.00

Total traded value

₹ 62.02

Upper Circuit

₹ 1162.30

Lower Circuit

₹ 774.90

info

REMUS PHARMACEUTICALS L Share Price Update

As of the latest trading session, REMUS PHARMACEUTICALS L share price is currently at ₹ 955.1, which is down by ₹ -982.15 from its previous closing. Today, the stock has fluctuated between ₹ 940.00 and ₹ 1021.80. Over the past year, REMUS PHARMACEUTICALS L has achieved a return of -5.57 %. In the last month alone, the return has been -4.18 %. Read More...

Investment Returns

Over 1 Month -4.18% Over 3 Months -11.49% Over 6 Months -19.55% Over 1 Year -5.57%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

REMUS PHARMACEUTICALS L fundamentals


  • Market cap (Cr)

    1,124.50

  • P/E Ratio (TTM)

    56.50

  • Beta

    1.09

  • Book Value / share

    205.55

  • Return on equity

    33.24%

  • EPS (TTM)

    16.89

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.00

info icon alternate text
  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

info icon alternate text

REMUS PHARMACEUTICALS L Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 79.16
Operating Expense 55.43
Net Profit 19.90
Net Profit Margin (%) 25.13
Earnings Per Share (EPS) 33.75
EBITDA 28.89
Effective Tax Rate (%) 25.30
Particulars MAR 2024 (Values in Cr)
Revenue 63.94
Operating Expense 44.40
Net Profit 16.62
Net Profit Margin (%) 25.99
Earnings Per Share (EPS) 29.40
EBITDA 23.81
Effective Tax Rate (%) 25.63
Particulars MAR 2023 (Values in Cr)
Revenue 45.03
Operating Expense 35.19
Net Profit 8.50
Net Profit Margin (%) 18.87
Earnings Per Share (EPS) 83.24
EBITDA 12.12
Effective Tax Rate (%) 25.50
Particulars MAR 2022 (Values in Cr)
Revenue 24.72
Operating Expense 20.83
Net Profit 3.43
Net Profit Margin (%) 13.87
Earnings Per Share (EPS) 34.34
EBITDA 4.85
Effective Tax Rate (%) 25.59
Particulars MAR 2024 (Values in Cr)
Book Value / Share 589.66
ROE % 29.91
ROCE % 32.68
Total Debt to Total Equity 0.13
EBITDA Margin 15.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 557.11
ROE % 33.24
ROCE % 41.05
Total Debt to Total Equity 0.09
EBITDA Margin 37.39
Particulars MAR 2023 (Values in Cr)
Book Value / Share 176.36
ROE % 66.10
ROCE % 68.21
Total Debt to Total Equity 0.32
EBITDA Margin 26.92
Particulars MAR 2022 (Values in Cr)
Book Value / Share 65.78
ROE % 70.58
ROCE % 92.25
Total Debt to Total Equity 0.05
EBITDA Margin 19.66
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3143.70
ROE % 41.09
ROCE % 48.98
Total Debt to Total Equity 0.12
EBITDA Margin 8.74
Particulars MAR 2020 (Values in Cr)
Book Value / Share 2020.30
ROE % 40.10
ROCE % 45.93
Total Debt to Total Equity 0.18
EBITDA Margin 10.40
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 26.86
Total Assets 257.27
Total Liabilities 257.27
Total Equity 104.33
Share Outstanding 1473000
Price to Book Ratio 12.38
Return on Assets (%) 8.37
Return on Capital (%) 18.59
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 23.84
Total Assets 98.05
Total Liabilities 98.05
Total Equity 82.06
Share Outstanding 1473000
Price to Book Ratio 12.38
Return on Assets (%) 17.15
Return on Capital (%) 20.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.03
Total Assets 34.66
Total Liabilities 34.66
Total Equity 19.13
Share Outstanding 1085000
Price to Book Ratio 0.00
Return on Assets (%) 24.53
Return on Capital (%) 31.4
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.14
Total Assets 15.86
Total Liabilities 15.86
Total Equity 6.57
Share Outstanding 1000000
Price to Book Ratio 0.00
Return on Assets (%) 21.65
Return on Capital (%) 50.73
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.83
Total Assets 11.01
Total Liabilities 11.01
Total Equity 3.14
Share Outstanding 10000
Price to Book Ratio 0.00
Return on Assets (%) 9.61
Return on Capital (%) 30.96
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.19
Total Assets 5.30
Total Liabilities 5.30
Total Equity 2.02
Share Outstanding 10000
Price to Book Ratio 0.00
Return on Assets (%) 15.30
Return on Capital (%) 34.11
Particulars MAR 2024 (Values in Cr)
Net Income 31.82
Cash from Operations 10.16
Cash from Investing -8.94
Cash from Financing 24.36
Net change in Cash 19.02
Free Cash Flow 10.80
Particulars MAR 2024 (Values in Cr)
Net Income 22.52
Cash from Operations 8.84
Cash from Investing -20.90
Cash from Financing 39.28
Net change in Cash 20.81
Free Cash Flow 9.48
Particulars MAR 2023 (Values in Cr)
Net Income 11.41
Cash from Operations 8.31
Cash from Investing -15.19
Cash from Financing 11.76
Net change in Cash 1.88
Free Cash Flow 11.04
Particulars MAR 2022 (Values in Cr)
Net Income 4.61
Cash from Operations 6.23
Cash from Investing -4.54
Cash from Financing -0.17
Net change in Cash 0.31
Free Cash Flow 6.30
Particulars MAR 2021 (Values in Cr)
Net Income 1.40
Cash from Operations 0.24
Cash from Investing -0.13
Cash from Financing -0.11
Net change in Cash -0.36
Free Cash Flow 0.31
Particulars MAR 2020 (Values in Cr)
Net Income 1.09
Cash from Operations 1.60
Cash from Investing -0.55
Cash from Financing 0.06
Net change in Cash 0.80
Free Cash Flow 2.16
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.45 27.82 1.99 279.33 34.11 / 77.70
BLISS GVS PHARMA LTD. 156.00 19.50 1.56 1643.78 103.10 / 184.95
CIPLA LTD. 1513.50 23.76 3.91 122246.58 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 328.70 12.58 2.66 967.40 170.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.45 36.45 5.76 279.33 34.11 / 77.70
AMRUTAJAN HEALTH LTD 712.85 40.55 6.30 2060.89 548.05 / 861.40
ASTRAZENECA PHARMA INDIA LTD. 9090.60 129.83 29.50 22726.50 6222.35 / 10653.05
BLISS GVS PHARMA LTD. 156.00 23.82 1.55 1643.78 103.10 / 184.95

REMUS PHARMACEUTICALS L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
954.25 -1.48 redarrow
red-green-graph indicator
13 Bearish
3 Bullish
  • 5 Days 958.00
  • 26 Days 963.60
  • 10 Days 956.20
  • 50 Days 980.30
  • 12 Days 956.20
  • 100 Days 1013.30
  • 20 Days 959.60
  • 200 Days 1036.50
1615.51 PIVOT

First Support

1247.12

First Resistance

1337.02

Second Support

1525.61

Second Resistance

1705.41

Third Support

1157.22

Third Resistance

1426.92

RSI

47.88

ADX

41.42

MACD

-7.44

Williams % R

-51.46

Commodity Channel Index (CCI)

60.66

Date

2025-07-04

Week

4125.00

Same Day

4200.00

Month

2276.00

1 Year

1.10

3 Year

1.03

Over 1 Month

-4.18%

down

Over 1 Year

-5.57%

down

Over 3 Months

-11.49%

down

Over 3 Years

61.96%

down

Over 6 Months

-19.55%

down

Over 5 Years

0.00%

down

REMUS PHARMACEUTICALS L shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
24.37%
Promoter Holdings
70.85%
FII
4.77%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Shah Arpit Deepakkumar 1038500.0 (17.63%) Shareholding of Promoter and Promoter Group
Roma Vinodbhai Shah 1012400.0 (17.18%) Shareholding of Promoter and Promoter Group
Swapnil Jatinbhai Shah 1000000.0 (16.97%) Shareholding of Promoter and Promoter Group
Anar Swapnil Shah 1000000.0 (16.97%) Shareholding of Promoter and Promoter Group
India Emerging Giants Fund Limited 259750.0 (4.41%) Public Shareholding
Rekha Gunavanth Kumar 64000.0 (1.09%) Public Shareholding
Hemant Ishwarlal Modi 58800.0 (1.0%) Shareholding of Promoter and Promoter Group
Renosen Pharmaceuticals Private Limited 53900.0 (0.91%) Shareholding of Promoter and Promoter Group
Sonal Hemantbhai Modi 4000.0 (0.07%) Shareholding of Promoter and Promoter Group
Mansi Aadarsh Shah 4000.0 (0.07%) Shareholding of Promoter and Promoter Group
Vinodkumar Gandalal Shah 3150.0 (0.05%) Shareholding of Promoter and Promoter Group
Remus Pharmaceuticals Llc 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Renosen Ventures Inc 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Suhana Ventures Llc 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Havix Group Inc 0.0 (0.0%) Shareholding of Promoter and Promoter Group
9488 Jackson Trail Llc 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Senores Pharmaceuticals Inc 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ami Hemant Modi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Darshil Jatinbhai Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ssas Family Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Svar Family Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Swapnil Shah Family Trust 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Esdee Enterprise 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Salvino Biosciences Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Gliesse Pharmaceuticals Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Espee Lifesciences Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Espee International Finechempharma Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ratnatris Pharmaceuticals Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Senores Pharmaceuticals Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Relius Lifesciences Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Healthy Life Nutraceuticals Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Espee Therapeutics Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Aelius Projects Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shah Vinodkumar Gandalal Huf 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Swapnil J Shah Huf 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Jatin Siddharthabhai Shah Huf 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Modi Hemantbhai Ishwarlal Huf 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Suhana Swapnil Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Vihaan Swapnil Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Athena Arpit Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pinkyben Jatinbhai Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Jatin Siddharthbhai Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Hemali Vakani 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Dhruvalben V. Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Chetnaben Vinodkumar Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Alkaben Dipakkumar Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Deepak Shah 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

REMUS PHARMACEUTICALS L corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
27 Oct 2023 2.0 Interim 28 Oct 2023 Equity shares
15 Sep 2023 2.0 Final 15 Sep 2023 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

REMUS PHARMACEUTICALS L Share Price

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad.

The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

The core business of the Company into three categories, which comprise of Manufacturing, through loan licencse or on contract manufacturing bassis, of approved finished formulations and distribution of the same in various countries; Trading of Active Pharmaceutical Ingredients and Technical Consultancy on preparation of reports on pharmaceutical dossiers.The product portfolio comprises of therapeutic drugs like ACE inhibitors, anaesthetic, Anti histamine, Antifungal, Anti-inflammatory, Antibiotic, Antidiabetic, Antipsychotic, Antiretroviral, Chronic Obstructive Pulmonary Disease, Asthma, Carcinoid tumours, CNS stimulants, Nasal decongestants, Potassium deficiency, Probiotic, Antispasmodic, Ocular-hypertension, Urology and Vitamin deficiency.

The Pharma business operations are supported by various contract manufacturers having facilities which are WHO GMP Compliant. The core strength lies in getting approved formulation manufactured through contract manufacturers under loan licence and marketing of formulations through marketing network across geographies.

The Company incorporated 'Relius Pharmaceuticals SRL' as a new subsidiary Company in Bolivia, effective on October 13, 2023.

The Company made an Initial Public Issue of 388000 Equity Shares of face value of Rs 10/- each by raising funds aggregating to Rs 47.68 Crore through Fresh Issue in May, 2023.

The Company acquired a majority stake (56.67%) of a USA based company, namely Espee Global Holdings LLC, making it a subsidiary of the Company effective on January 1, 2024.

Parent organization Indian Private
NSE symbol REMUS
Founded 2015
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Remus Pharmaceuticals Ltd?

Answer Field

Remus Pharmaceuticals Ltd share price is for NSE ₹ 955.10 & for BSE ₹ 0.00 as on Jul 04 2025 03:29 PM.

What is the Market Cap of Remus Pharmaceuticals Ltd Share?

Answer Field

The market cap of Remus Pharmaceuticals Ltd for NSE ₹ 140.68 & for BSE ₹ 0.00 as on Jul 04 2025 03:29 PM.

What is the 52 Week High and Low of Remus Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Remus Pharmaceuticals Ltd for NSE is ₹ 1,417.38 and ₹ 890.53 and for BSE is ₹ 0.00 and ₹ 0.00.

What is 1 year return for Remus Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -5.57%.

What is the P/E Ratio of Remus Pharmaceuticals Ltd Share?

Answer Field

As on Jul 04 2025 03:29 PM the price-to-earnings (PE) ratio for Remus Pharmaceuticals Ltd share is 56.50.

What is the PB ratio of Remus Pharmaceuticals Ltd Share?

Answer Field

As on Jul 04 2025 03:29 PM, the price-to-book (PB) ratio for Remus Pharmaceuticals Ltd share is 205.55.

How to Buy Remus Pharmaceuticals Ltd Share?

Answer Field

You can trade in Remus Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Remus Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Remus Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Remus Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|